Survey: Transitioning from animal to patient-derived in vitro models

Continuing improvements in the development of patient-derived in vitro models of tissues and disease states, combined with regulatory changes such as the FDA Modernization Act 2.0, which removes the requirement for all drugs to have been safety tested in animal models prior to their approval, have increased the demand for methods and protocols that assist with the standardization, integration and application of these models.

We want to hear how these changes have impacted you: how are you using patient-derived cell models or do you want to start? What are the challenges of using and integrating them into existing workflows? And what still needs to improve to help these models reach their full potential? Let us know in the survey below.